• Forum
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Get in touch
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

OncoZenge

6.63 SEK-3.91 %10.7, 9.16
Less than 1K followers

ONCOZ

First North Stockholm

Biotechnology & Pharmaceuticals

Health Care

Overview
Financials & Estimates
Ownership
Dividend
Investor consensus
Compare
-3.91 %
-6.49 %
+15.30 %
+11.43 %
-1.92 %
+5.74 %
+7.80 %
-36.25 %
-45.82 %

OncoZenge is a Swedish pharmaceutical company that develops treatments for pain relief in patients suffering from oral pain caused by radiation therapy and chemotherapy for cancer. The company's product candidate is undergoing further development after completing phase 2 studies to form the basis for application for regulatory market approvals and commercialization. OncoZenge is headquartered in Bromma.

Read more
Market cap
108.62M SEK
Turnover
16.77K SEK
Revenue
2.66M
EBIT %
-592.61 %
P/E
-
Dividend yield-%
-
Revenue and EBIT-%
EPS and dividend
Financial calendar
3.9
2026

Interim report Q2'26

11.11
2026

Interim report Q3'26

All
Press releases
ShowingAll content types

Revenue and EBIT-%

Revenue M

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Press release07.07.2026, 15.25

OncoZenge AB Announces Enrollment of First Patient in Pivotal Phase III BEAM-Pain Trial of BupiZenge™

OncoZenge
Regulatory press release03.07.2026, 17.10

OncoZenge Extends the Payment Deadline for Subscription Proceeds

OncoZenge
Regulatory press release26.06.2026, 14.15

OncoZenge Extends the Payment Deadline for Subscription Proceeds

OncoZenge

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Regulatory press release05.06.2026, 15.10

OncoZenge resolves on a directed share issue to Sichuan Yangtian Bio-Pharmaceutical pursuant to existing investment agreement

OncoZenge
Press release03.06.2026, 09.30

OncoZenge AB Appoints Linda Nord as Head of Regulatory Affairs

OncoZenge
Press release02.06.2026, 09.50

OncoZenge Receives CTA Approval Milestone Payment From Molteni Farmaceutici

OncoZenge
Regulatory press release27.05.2026, 15.15

BULLETIN FROM THE ANNUAL GENERAL MEETING OF ONCOZENGE

OncoZenge
Press release26.05.2026, 12.19

Redeye: OncoZenge (Q1 Review): Final CTA approval received, initiating pivotal study

OncoZenge
Regulatory press release26.05.2026, 11.20

OncoZenge Receives European Regulatory Approval to Start Pivotal Phase III Trial of BupiZenge™

OncoZenge
Regulatory press release26.05.2026, 08.00

OncoZenge AB Interim Report January 1 - March 31, 2026

OncoZenge
Regulatory press release22.05.2026, 07.00

OncoZenge enters into a loan agreement of SEK 2 million with Linc AB

OncoZenge
Press release19.05.2026, 13.40

OncoZenge Provides Regulatory Update on BupiZenge™ Phase III Trial

OncoZenge
Regulatory press release30.04.2026, 08.00

OncoZenge AB Publishes Annual Report for 2025

OncoZenge
Press release28.04.2026, 14.50

OncoZenge Receives Conditional Acceptance for the Clinical Phase III Trial (‘BEAM-Pain’) of BupiZenge™ from European Authorities

OncoZenge
Regulatory press release24.04.2026, 08.00

Notice of the Annual General Meeting of OncoZenge AB (publ)

OncoZenge
Press release02.04.2026, 12.55

OncoZenge Confirms Submission of Responses to EMA on the BupiZenge™ Phase III Trial (BZ003)

OncoZenge
Press release01.04.2026, 09.15

OncoZenge Reports Positive Stability Results for BupiZenge™ as Key Enabler for the Upcoming Phase III Trial

OncoZenge
Press release26.02.2026, 15.29

Redeye: OncoZenge (Q4 review): Final preparations ahead of phase III

OncoZenge
Regulatory press release26.02.2026, 08.00

OncoZenge AB Year-end Report January 1 – December 31, 2025

OncoZenge
Press release12.02.2026, 10.22

OncoZenge Receives Investment Capital From Yangtian Bio-Pharmaceutical

OncoZenge